In this study, a laminated woven bamboo/woven E glass/unsaturated polyester composite is developed to combat a ballistic impact from bullet under shooting test. The aim of this study is to understand the fundamental e...In this study, a laminated woven bamboo/woven E glass/unsaturated polyester composite is developed to combat a ballistic impact from bullet under shooting test. The aim of this study is to understand the fundamental effects of the woven bamboo arrangement towards increasing ballistic resistance properties. The work focusses on the ballistic limit test known as NIJ V50, which qualifies materials to be registered for use in combat armor panels. The results show that the composites withstood 482.5 m/s ± 5 limit of bullet velocity, satisfying the NIJ test at level II. The findings give a strong sound basis decision to engineers whether or not green composites are qualified to replace synthetic composites in certain engineering applications.展开更多
Data Integrity is a critical component of Data lifecycle management. Its importance increases even more in a complex and dynamic landscape. Actions like unauthorized access, unauthorized modifications, data manipulati...Data Integrity is a critical component of Data lifecycle management. Its importance increases even more in a complex and dynamic landscape. Actions like unauthorized access, unauthorized modifications, data manipulations, audit tampering, data backdating, data falsification, phishing and spoofing are no longer restricted to rogue individuals but in fact also prevalent in systematic organizations and states as well. Therefore, data security requires strong data integrity measures and associated technical controls in place. Without proper customized framework in place, organizations are prone to high risk of financial, reputational, revenue losses, bankruptcies, and legal penalties which we shall discuss further throughout this paper. We will also explore some of the improvised and innovative techniques in product development to better tackle the challenges and requirements of data security and integrity.展开更多
Granulocytic or myeloid sarcoma (MS) is a rare neoplastic condition consisting of a tumor mass of myeloid blasts with or without maturation occurring at an anatomical site other than the bone marrow the association be...Granulocytic or myeloid sarcoma (MS) is a rare neoplastic condition consisting of a tumor mass of myeloid blasts with or without maturation occurring at an anatomical site other than the bone marrow the association between tuberculosis and MS is extremely rare. A 21-year-old female patient presented cough, sore throat and a suppurative swollen gum for 10 days prior to hospital admission. Physical examination revealed moderate pallor and swollen inferior gum. CBC revealed Hb6.5 g/dL, hematocrit 18.4% MCV 97 fL MCH 34 pg, WBC 18.5 ′ 109/μL (1 My/3 Bt/69 Sg/1 Eo/0 Ba/20 Ly/6 Mo), Platelets 43 ′ 109/μL. The peripheral blood smear presented with 3% blast cells (type 1) and granulocytic dysplasia. Bone marrow biopsy showed 100% cellularity. 50% of cells were from granulocytic precursors, diagnosis of granulocytic sarcoma. The diagnosis of AML was established: granulocytic sarcoma with massive gum infiltration (immature granulocytic cells) and 10% of blasts in bone marrow. The patient received induction chemotherapy (3 + 7 daunorubicin 90 mg/m2), and gum tissue culture was positive for Mycobacterium tuberculosis. Simultaneously, a qRT- PCR test confirmed the same bacteria in the gum tissue. Patient treated with isoniazid, rifampicin, pyrazinamide and ethambutol ciprofloxacin and amikacin). Remission was achieved and the patient was submitted for consolidation/ intensification (HiDAC x3) schema and referred to allogeneic HSCT. After induction and full hematological recovery there was no further evidence or recurrence of fever and lytic lesions. Currently patient is under CR and ling follow up (48 months) did not show recurrence of either AML or tuberculosis.展开更多
Background:Glecirasib,an inhibitor of Kirsten rat sarcoma viral oncogene homolog glycine-to-cysteine substitution at codon 12(KRAS G12C),has exhibited clinical activity in non-small-cell lung cancer(NSCLC)and colorect...Background:Glecirasib,an inhibitor of Kirsten rat sarcoma viral oncogene homolog glycine-to-cysteine substitution at codon 12(KRAS G12C),has exhibited clinical activity in non-small-cell lung cancer(NSCLC)and colorectal cancer(CRC).Here,we investigated the efficacy and safety of glecirasib in patients with pancreatic ductal adenocarcinoma(PDAC)and other solid tumors(excluding NSCLC and CRC)that rarely harbor the KRAS G12C mutation but for which effective treatment options remain limited.Methods:We conducted and analyzed two open-label,phase I/II trials in adult patients with KRAS G12C mutant solid tumors,in which glecirasib was administered orally.The two trials had similar eligibility criteria and endpoints but differed in the regions of patient recruitment.We performed a pooled analysis of all patients,excluding NSCLC and CRC,from both trials.The primary end-point in the pooled population was objective response rate(ORR).Efficacy and safety were assessed in patients who received at least one dose of glecirasib.Results:As of June 30,2024,the pooled analysis included 54 patients who were treated with glecirasib:32 PDACs,8 biliary tract cancers(BTCs),4 small intestinal cancers,3 gastric cancers,2 appendiceal cancers,and 5 other tumors.At baseline,24 received≥two prior lines of systemic therapy.Of the 53 efficacyevaluable patients,the confirmed ORR was 50.9%(95%confidence interval[CI],36.8%-64.9%),with an ORR of 46.9%(95%CI,29.1%-65.3%)in PDAC patients.Among other solid tumors,ORR was 71.4%(5/7)in BTC,100%(4/4)in small intestinal cancer,and 66.7%(2/3)in gastric cancer.Median progression-free survival and median overall survival were 6.9 and 10.8 months,respectively,in the overall population,and 5.5 and 10.8 months,respectively,in patients with PDAC.Treatment-related adverse events(TRAEs)of any grade occurred in 94.4%patients,with grade≥3 TRAEs in 27.8%.No fatal TRAEs or TRAEs leading to treatment discontinuation occurred.Conclusions:Glecirasib showed promising efficacy and was well tolerated in patients with PDAC and other advanced solid tumors(beyond NSCLC and CRC),warranting further expedited clinical development in this patient population.Trial registration:ClinicalTrials.gov identifier:NCT05009329 and NCT05002270.展开更多
Importance:Urinary tract infection(UTI)is one of the most common infections encountered in infancy and childhood.Despite the emerging problem of antibiotic resistance in recent years,the use of antibiotics for better ...Importance:Urinary tract infection(UTI)is one of the most common infections encountered in infancy and childhood.Despite the emerging problem of antibiotic resistance in recent years,the use of antibiotics for better management of UTIs is inevitable.Objective:This study aims to explore the efficacy and adverse effects of the available antimicrobial agents that are used in pediatric UTIs in low-and middle-income countries(LMICs).Methods:Five electronic databases were searched to identify relevant articles.Two reviewers independently performed screening,data extraction,and quality assessment of the available literature.Randomized controlled trials providing antimicrobial interventions in both male and female participants within the age range of 3 months to 17 years in LMICs were included.Results:Six randomized controlled trials from 13 LMICs were included in this review(four trials explored the efficacy).Due to high heterogeneity across the studies,a meta-analysis was not performed.Other than attrition and reporting bias,the risk of bias was moderate to high due to poor study designs.The differences in the efficacy and adverse events of different antimicrobials were not found to be statistically significant.Interpretation:This review indicates the necessity for additional clinical trials on children from LMICs with more significant sample numbers,adequate intervention periods,and study design.展开更多
The impact of South-South cooperation(SSC)has been bolstered in the context of implementing the International Conference on Population and Development(ICPD)Programme of Action.In the past 25 years since ICPD in 1994,r...The impact of South-South cooperation(SSC)has been bolstered in the context of implementing the International Conference on Population and Development(ICPD)Programme of Action.In the past 25 years since ICPD in 1994,remarkable progress and achievements have been made in promoting SSC in population and develop-ment.China has been committed to working with developing countries,UN agen-cies and international organizations to advance ICPD under the framework of SSC.As the landscape of international development assistance has been changing and the ICPD remains as an unfinished agenda,the SSC has increasingly recognized the importance of effective financial inclusion policy in the implementation of the ICPD and the 2030 Agenda for Sustainable Development.The international community has recently identified seven strategic priority areas for SSC in the next few years,i.e.,(1)population dynamics and development;(2)universal access to reproduc-tive health and family planning services;(3)women’s,children’s and adolescents’health;(4)healthy ageing;(5)migration;(6)health and poverty alleviation;and(7)ending sexual and gender-based violence.The institutionalization and operation-alization remain as critical challenges,and special attention needs to be given to address these issues.Stronger political commitments,enhanced capacity building,better coordination and partnerships establishment of the SSC Center of Excellence,adequate resource mobilization and more evidence-based researches and systematic evaluation are recommended as future strategies for further promoting the SSC in population and development.展开更多
基金the Fundamental Research Grant Scheme(FRGS)1/2013/TK01/UPNM/01/2Universiti Pertahanan National Malaysia(UPNM)for supporting the research work
文摘In this study, a laminated woven bamboo/woven E glass/unsaturated polyester composite is developed to combat a ballistic impact from bullet under shooting test. The aim of this study is to understand the fundamental effects of the woven bamboo arrangement towards increasing ballistic resistance properties. The work focusses on the ballistic limit test known as NIJ V50, which qualifies materials to be registered for use in combat armor panels. The results show that the composites withstood 482.5 m/s ± 5 limit of bullet velocity, satisfying the NIJ test at level II. The findings give a strong sound basis decision to engineers whether or not green composites are qualified to replace synthetic composites in certain engineering applications.
文摘Data Integrity is a critical component of Data lifecycle management. Its importance increases even more in a complex and dynamic landscape. Actions like unauthorized access, unauthorized modifications, data manipulations, audit tampering, data backdating, data falsification, phishing and spoofing are no longer restricted to rogue individuals but in fact also prevalent in systematic organizations and states as well. Therefore, data security requires strong data integrity measures and associated technical controls in place. Without proper customized framework in place, organizations are prone to high risk of financial, reputational, revenue losses, bankruptcies, and legal penalties which we shall discuss further throughout this paper. We will also explore some of the improvised and innovative techniques in product development to better tackle the challenges and requirements of data security and integrity.
文摘Granulocytic or myeloid sarcoma (MS) is a rare neoplastic condition consisting of a tumor mass of myeloid blasts with or without maturation occurring at an anatomical site other than the bone marrow the association between tuberculosis and MS is extremely rare. A 21-year-old female patient presented cough, sore throat and a suppurative swollen gum for 10 days prior to hospital admission. Physical examination revealed moderate pallor and swollen inferior gum. CBC revealed Hb6.5 g/dL, hematocrit 18.4% MCV 97 fL MCH 34 pg, WBC 18.5 ′ 109/μL (1 My/3 Bt/69 Sg/1 Eo/0 Ba/20 Ly/6 Mo), Platelets 43 ′ 109/μL. The peripheral blood smear presented with 3% blast cells (type 1) and granulocytic dysplasia. Bone marrow biopsy showed 100% cellularity. 50% of cells were from granulocytic precursors, diagnosis of granulocytic sarcoma. The diagnosis of AML was established: granulocytic sarcoma with massive gum infiltration (immature granulocytic cells) and 10% of blasts in bone marrow. The patient received induction chemotherapy (3 + 7 daunorubicin 90 mg/m2), and gum tissue culture was positive for Mycobacterium tuberculosis. Simultaneously, a qRT- PCR test confirmed the same bacteria in the gum tissue. Patient treated with isoniazid, rifampicin, pyrazinamide and ethambutol ciprofloxacin and amikacin). Remission was achieved and the patient was submitted for consolidation/ intensification (HiDAC x3) schema and referred to allogeneic HSCT. After induction and full hematological recovery there was no further evidence or recurrence of fever and lytic lesions. Currently patient is under CR and ling follow up (48 months) did not show recurrence of either AML or tuberculosis.
文摘Background:Glecirasib,an inhibitor of Kirsten rat sarcoma viral oncogene homolog glycine-to-cysteine substitution at codon 12(KRAS G12C),has exhibited clinical activity in non-small-cell lung cancer(NSCLC)and colorectal cancer(CRC).Here,we investigated the efficacy and safety of glecirasib in patients with pancreatic ductal adenocarcinoma(PDAC)and other solid tumors(excluding NSCLC and CRC)that rarely harbor the KRAS G12C mutation but for which effective treatment options remain limited.Methods:We conducted and analyzed two open-label,phase I/II trials in adult patients with KRAS G12C mutant solid tumors,in which glecirasib was administered orally.The two trials had similar eligibility criteria and endpoints but differed in the regions of patient recruitment.We performed a pooled analysis of all patients,excluding NSCLC and CRC,from both trials.The primary end-point in the pooled population was objective response rate(ORR).Efficacy and safety were assessed in patients who received at least one dose of glecirasib.Results:As of June 30,2024,the pooled analysis included 54 patients who were treated with glecirasib:32 PDACs,8 biliary tract cancers(BTCs),4 small intestinal cancers,3 gastric cancers,2 appendiceal cancers,and 5 other tumors.At baseline,24 received≥two prior lines of systemic therapy.Of the 53 efficacyevaluable patients,the confirmed ORR was 50.9%(95%confidence interval[CI],36.8%-64.9%),with an ORR of 46.9%(95%CI,29.1%-65.3%)in PDAC patients.Among other solid tumors,ORR was 71.4%(5/7)in BTC,100%(4/4)in small intestinal cancer,and 66.7%(2/3)in gastric cancer.Median progression-free survival and median overall survival were 6.9 and 10.8 months,respectively,in the overall population,and 5.5 and 10.8 months,respectively,in patients with PDAC.Treatment-related adverse events(TRAEs)of any grade occurred in 94.4%patients,with grade≥3 TRAEs in 27.8%.No fatal TRAEs or TRAEs leading to treatment discontinuation occurred.Conclusions:Glecirasib showed promising efficacy and was well tolerated in patients with PDAC and other advanced solid tumors(beyond NSCLC and CRC),warranting further expedited clinical development in this patient population.Trial registration:ClinicalTrials.gov identifier:NCT05009329 and NCT05002270.
文摘Importance:Urinary tract infection(UTI)is one of the most common infections encountered in infancy and childhood.Despite the emerging problem of antibiotic resistance in recent years,the use of antibiotics for better management of UTIs is inevitable.Objective:This study aims to explore the efficacy and adverse effects of the available antimicrobial agents that are used in pediatric UTIs in low-and middle-income countries(LMICs).Methods:Five electronic databases were searched to identify relevant articles.Two reviewers independently performed screening,data extraction,and quality assessment of the available literature.Randomized controlled trials providing antimicrobial interventions in both male and female participants within the age range of 3 months to 17 years in LMICs were included.Results:Six randomized controlled trials from 13 LMICs were included in this review(four trials explored the efficacy).Due to high heterogeneity across the studies,a meta-analysis was not performed.Other than attrition and reporting bias,the risk of bias was moderate to high due to poor study designs.The differences in the efficacy and adverse events of different antimicrobials were not found to be statistically significant.Interpretation:This review indicates the necessity for additional clinical trials on children from LMICs with more significant sample numbers,adequate intervention periods,and study design.
文摘The impact of South-South cooperation(SSC)has been bolstered in the context of implementing the International Conference on Population and Development(ICPD)Programme of Action.In the past 25 years since ICPD in 1994,remarkable progress and achievements have been made in promoting SSC in population and develop-ment.China has been committed to working with developing countries,UN agen-cies and international organizations to advance ICPD under the framework of SSC.As the landscape of international development assistance has been changing and the ICPD remains as an unfinished agenda,the SSC has increasingly recognized the importance of effective financial inclusion policy in the implementation of the ICPD and the 2030 Agenda for Sustainable Development.The international community has recently identified seven strategic priority areas for SSC in the next few years,i.e.,(1)population dynamics and development;(2)universal access to reproduc-tive health and family planning services;(3)women’s,children’s and adolescents’health;(4)healthy ageing;(5)migration;(6)health and poverty alleviation;and(7)ending sexual and gender-based violence.The institutionalization and operation-alization remain as critical challenges,and special attention needs to be given to address these issues.Stronger political commitments,enhanced capacity building,better coordination and partnerships establishment of the SSC Center of Excellence,adequate resource mobilization and more evidence-based researches and systematic evaluation are recommended as future strategies for further promoting the SSC in population and development.
